Analysts identify Agilent Technologies as a potential suitor for diagnostics firm Qiagen NV. Qiagen NV stock surged 16% this week. The surge followed reports that Qiagen is exploring a sale.
JPMorgan analyst Casey Woodring names Agilent and Danaher Corporation as the most likely suitors. Woodring cites their flexibility in pursuing large-scale transactions.
Wolfe Research analyst Doug Schenkel suggests a deal for Qiagen is now more feasible. He attributes this to a CEO change at the company. This change removes a primary roadblock seen during the failed 2020 takeover attempt by Thermo Fisher Scientific.